Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Sep;35(5):1364-1374.
doi: 10.1007/s13577-022-00752-y. Epub 2022 Jul 21.

Long non‑coding RNA PART1: dual role in cancer

Rui Ran  1   2 , Chao-Yang Gong  1   2 , Zhi-Qiang Wang  1   2 , Wen-Ming Zhou  1   2 , Shun-Bai Zhang  1   2 , Yong-Qiang Shi  1   2 , Chun-Wei Ma  1   2 , Hai-Hong Zhang  3
Affiliations
Review

Long non‑coding RNA PART1: dual role in cancer

Rui Ran et al. Hum Cell. 2022 Sep.

Abstract

Increasing evidence has shown that long non-coding RNAs (lncRNAs), which are non-coding endogenous single-stranded RNAs, play an essential role in various physiological and pathological processes through transcriptional interference, post-transcriptional regulation, and epigenetic modification. Moreover, lncRNAs, as oncogenes or tumor suppressor genes, play an important role in the occurrence and development of human cancers. Prostate androgen-regulated transcript 1 (PART1) was initially identified as a carcinogenic lncRNA in prostate adenomas. The upregulated expression of PART1 plays a tumor-promoting role in liver, prostate, lung cancers, and other tumors. In contrast, the expression of PART1 is downregulated in esophageal squamous cell carcinoma, glioma, and other tumors, which may inhibit the tumor. PART1 plays a dual role in cancer and regulates cell proliferation, apoptosis, invasion, and metastasis through a variety of potential mechanisms. These findings suggest that PART1 is a promising tumor biomarker and therapeutic target. This article reviews the biological functions, related mechanisms, and potential clinical significance of PART1 in a variety of human cancers.

Keywords: Cancer; Mechanisms; PART1; lncRNA.

PubMed Disclaimer

References

    1. Siegel RL, et al. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33. - PubMed - DOI
    1. Bugter JM, Fenderico N, Maurice MM. Mutations and mechanisms of WNT pathway tumour suppressors in cancer. Nat Rev Cancer. 2021;21(1):5–21. - PubMed - DOI
    1. Chang WH, Lai AG. An immunoevasive strategy through clinically-relevant pan-cancer genomic and transcriptomic alterations of JAK-STAT signaling components. Mol Med. 2019;25(1):46. - PubMed - PMC - DOI
    1. Peng X, et al. A-to-I RNA editing contributes to proteomic diversity in cancer. Cancer Cell. 2018;33(5):817-828.e7. - PubMed - PMC - DOI
    1. Sreekumar A, et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009;457(7231):910–4. - PubMed - PMC - DOI

LinkOut - more resources